AKBA ▼ -24.6% - Akebia Therapeutics, Inc.
$AKBA - Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin
05-NOV-2026 07:00 AM ET
Share this post
More filings for $AKBA
AKBA ▼ -26.1% - Akebia Therapeutics, Inc.Nov 5, 2026AKBA ▲ +1.8% - Akebia Therapeutics, Inc.Oct 26, 2026AKBA ▼ -2.2% - Akebia Therapeutics, Inc.Oct 6, 2026AKBA ▼ -4.3% - Akebia Therapeutics, Inc.Oct 1, 2026AKBA ▲ +1.1% - Akebia Therapeutics, Inc.Sep 14, 2026AKBA ▲ +3.3% - Akebia Therapeutics, Inc.Sep 1, 2026
View full $AKBA filing history →💬 Comments
Loading comments…
Leave a comment